Reminder: Invitation to Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting
June 07, 2021 at 08:07 am EDT
Share
Investor Update
Reminder: Invitation to Roche's virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting
We are pleased to invite investors and analysts to participate in our virtual event on Monday, 14 June 2021, highlighting Roche data presented during the congress scientific program from June 7 - 11 2021.
16:00 - 17:00 CEST / 15:00 - 16:00 BST
10:00 - 11:00 am EDT / 7:00 - 8:00 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. >click here
Agenda
JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam
RAINBOWFISH: A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Q&A
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Paulo Fontoura, M.D. Ph.D., Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Kavita Patel, Lifecycle Leader SMA, Global Product Strategy
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via >ir.roche.com
Best regards,
Karl Mahler
Head of Investor Relations and Roche Group Planning
Gerard Tobin
Investor Relations Officer
Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Roche Holding AG published this content on 07 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2021 12:06:04 UTC.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
ROCHE HOLDING AG 
